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BACKGROUND
Coronary revascularization guided by fractional flow reserve (FFR) is associated 
with better patient outcomes after the procedure than revascularization guided by 
angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), 
an alternative measure that does not require the administration of adenosine, will 
offer benefits similar to those of FFR.
METHODS
We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio, 
to undergo either iFR-guided or FFR-guided coronary revascularization. The primary 
end point was the 1-year risk of major adverse cardiac events, which were a com-
posite of death from any cause, nonfatal myocardial infarction, or unplanned re-
vascularization. The trial was designed to show the noninferiority of iFR to FFR, 
with a margin of 3.4 percentage points for the difference in risk.
RESULTS
At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the 
iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk, 
−0.2 percentage points; 95% confidence interval [CI], −2.3 to 1.8; P<0.001 for 
noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P = 0.78). The risk of each 
component of the primary end point and of death from cardiovascular or noncar-
diovascular causes did not differ significantly between the groups. The number of 
patients who had adverse procedural symptoms and clinical signs was signifi-
cantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385 
patients [30.8%], P<0.001), and the median procedural time was significantly 
shorter (40.5 minutes vs. 45.0 minutes, P = 0.001).
CONCLUSIONS
Coronary revascularization guided by iFR was noninferior to revascularization 
guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The 
rate of adverse procedural signs and symptoms was lower and the procedural time 
was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE-FLAIR 
ClinicalTrials.gov number, NCT02053038.)
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For the past 20 years, physiological measurements obtained during invasive pro-cedures have been used to guide coronary 
revascularization. Pioneering work supported the 
use of flow measurements to make safe decisions 
about revascularization,1,2 but this approach was 
soon superseded by the use of fractional flow 
reserve (FFR), which measures pressure as a sur-
rogate of flow to estimate the severity of steno-
sis.3-5 FFR was successful largely because of its 
technical simplicity and because clinical trials 
showed that it was associated with improved 
clinical outcomes after percutaneous coronary 
intervention (PCI).6,7 Consequently, FFR is now 
included in the appropriate-use criteria for coro-
nary angiography and in the American College of 
Cardiology–American Heart Association–European 
Society of Cardiology guidelines; despite these 
recommendations, its adoption remains limited.8-10
FFR must be measured during maximal hyper-
emia, which is typically induced with the admin-
istration of a potent intravenous or intracoronary 
vasodilator, such as adenosine.11 Several studies 
have questioned the need for the administration 
of a vasodilator to assess stenosis severity.12-14 In 
these studies, investigators found that in deter-
mining stenosis severity, FFR was not superior to 
the instantaneous wave-free ratio (iFR), a pressure-
derived index of stenosis severity that is not ob-
tained with the administration of a vasodilator. 
We aimed to determine the efficacy and safety 
of an iFR-guided strategy versus an FFR-guided 
strategy for coronary revascularization.
Me thods
Trial Design and Management
DEFINE-FLAIR (Functional Lesion Assessment of 
Intermediate Stenosis to Guide Revascularisation) 
is a multicenter, international, randomized, 
blinded trial in which iFR is being compared 
with FFR for physiologically guided coronary 
revascularization. The trial, which is ongoing, is 
being performed at 49 interventional sites across 
19 countries on 4 continents. The 1-year out-
comes, on which the primary trial analysis is 
based, are reported here.
The trial was designed by the steering com-
mittee (for a list of committee members, see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). Central ethics 
approval was granted by the National Research 
Ethics Service Committee London, and local ethics 
approval was granted at each participating site. 
The trial is funded by an unrestricted educa-
tional grant from Philips Volcano, which had no 
role in the design of the trial, the collection or 
analysis of the data, the writing of the manu-
script, or the decision to submit the manuscript 
for publication.
Trial management and oversight were per-
formed by personnel at the Imperial College 
Trials Unit, Imperial College London, who main-
tained the clinical database and conducted all 
the data analyses independent of the funder. A 
risk assessment established that the trial was of 
low risk to the patients; therefore, no data and 
safety monitoring board was established. The 
first draft of the manuscript was written by the 
first author, and all the authors participated in 
trial oversight, approved all subsequent drafts of 
the manuscript, and made the decision to sub-
mit the manuscript for publication. The steering 
committee and all the authors vouch for the ac-
curacy and completeness of the data and analy-
ses and for the fidelity of the study to the trial 
protocol and statistical analysis plan, which are 
available at NEJM.org.
Population
Patients who had undergone coronary angiogra-
phy were assessed for trial eligibility. Patients 
were eligible for inclusion in the trial if they had 
coronary artery disease with at least one native 
artery in which the stenosis was of questionable 
physiological severity (typically, an artery with 
40 to 70% stenosis of the diameter on visual as-
sessment). Patients with tandem stenoses (i.e., 
stenoses separated by more than 10 mm within 
a single vessel) that would require independent 
evaluation and treatment were excluded. A full 
list of inclusion and exclusion criteria is provided 
in Table S1 in the Supplementary Appendix. No 
exclusions were made on the basis of heart rate 
or rhythm. Written informed consent was ob-
tained from all the patients before their enroll-
ment in the trial.
Randomization
Eligible patients were randomly assigned to un-
dergo revascularization guided by either FFR or 
iFR. Randomization was performed with the use 
of an automated and validated online random-
ization tool (SRUB, Imperial College London). 
During the trial procedures, investigators were 
allowed to obtain FFR or iFR measurements only 
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in accordance with group assignment. Verification 
of the data was performed in each patient with 
the use of the electronic physiology record, 
which was uploaded directly from the physiolog-
ical console for each patient into the electronic 
clinical record (Fig. S1 in the Supplementary 
Appendix). During the procedure, patients were 
not told which technique was used for physio-
logical assessment, and they remained unaware 
of their group assignment throughout the entire 
course of the trial. The research nurses and doc-
tors who were responsible for the follow-up visits 
were also unaware of the group assignments.
Procedure
Before the FFR or iFR measurement was ob-
tained, intracoronary nitrates were administered 
to control vasomotor tone. The physiological 
measurements were obtained in the routine 
manner with the use of a coronary-pressure 
guidewire (Philips Volcano) (Figs. S1 and S2 in 
the Supplementary Appendix). Physiological as-
sessment was performed in all vessels with ques-
tionable stenosis severity. In patients with an 
acute coronary syndrome, physiological assess-
ment was performed in only nonculprit vessels, 
after the culprit vessel had been revascularized. 
Prespecified treatment thresholds were an FFR of 
0.80 and an iFR of 0.89 (Fig. S3 in the Supple-
mentary Appendix). When the FFR or iFR for a 
given stenosis was equal to or lower than the 
prespecified threshold, the stenosis was revascu-
larized with a drug-eluting stent or a bioresorb-
able vascular scaffold or by coronary-artery by-
pass grafting (CABG). When the FFR or iFR was 
higher than the prespecified threshold, treatment 
was deferred. When multivessel revasculariza-
tion was attempted, investigators could choose 
to prespecify a staged treatment plan, with the 
staged procedure performed within 60 days. Ad-
verse procedural signs and symptoms were docu-
mented.
Routine clinical follow-up assessments were 
performed at 30 days and at 1 year, and follow-
up by telephone was conducted at 6 months. 
Complete monitoring of every electronic clinical 
record was performed, and the data were con-
firmed by on-site source-document verification 
in a randomly selected 30% of patients.
End Points
The primary end point was the 1-year risk of 
major adverse cardiac events, which were a com-
posite of death, nonfatal myocardial infarction, 
or unplanned revascularization. Death was con-
sidered to be from cardiovascular causes unless 
an unequivocal noncardiovascular cause was es-
tablished. Myocardial infarction was classified 
as either spontaneous or periprocedural and as 
either ST-segment elevation myocardial infarction 
(STEMI) or non-STEMI (NSTEMI). Revasculariza-
tion was considered to be unplanned when it was 
not the index procedure and was not identified 
at the time of the index procedure as a staged 
procedure to occur within 60 days. Detailed end-
point definitions, which did not change after the 
commencement of the trial, are provided in the 
Supplementary Appendix.
End-point events were adjudicated with the use 
of anonymized source documentation by a com-
mittee of international experts who were not 
part of the steering committee. A consensus 
decision was made on the basis of prespecified 
end-point definitions. Members of the events 
committee remain unaware of the identities of 
the patients and their group assignments.
Statistical Analysis
The prespecified trial hypothesis was that iFR 
would be noninferior to FFR with respect to the 
risk of major adverse cardiac events at 1 year 
among patients undergoing physiologically guid-
ed revascularization. We based the sample size 
on an assumed annual rate of primary end-point 
events of 8.5% in a population that includes a 
mix of patients with either stable coronary dis-
ease or acute coronary syndromes15; given this 
rate, we calculated that a sample size of 2305 
patients would provide the trial with 90% power 
to detect the noninferiority of iFR to FFR, with 
the use of a noninferiority margin of 3.4 percent-
age points for the difference in risk, at a type I 
error rate of 5%. To allow for attrition, the target 
sample size was set at 2500 patients.
Both a risk-difference analysis and a time-to-
event analysis were performed. The time-to-event 
analysis was conducted with the use of the 
Kaplan–Meier method. A Cox survival model 
was used to derive hazard ratios. For the results 
of both analyses, two-sided 95% confidence in-
tervals (whose upper limits correspond to the 
upper limits of one-sided 97.5% confidence in-
tervals) and two-sided 99% confidence intervals 
(whose upper limits correspond to the upper 
limits of one-sided 99.5% confidence intervals) 
are reported. The validity of the proportional-
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hazards assumption was tested with Schoenfeld 
residuals. There were no signs of violation of the 
proportional-hazards assumption.
Patients who withdrew from the study before 
they reached 1 year of follow-up and who were 
event-free at their last visit were excluded from 
the risk-difference analysis for the primary end 
point and its components. Data for these pa-
tients were censored at the time of withdrawal 
for the time-to-event analysis. Patients who had 
a myocardial infarction or an unplanned revas-
cularization before withdrawing from the study 
were included in the risk-difference analysis.
R esult s
Patients and Procedures
During the recruitment period (January 2014 to 
December 2015), a total of 2535 patients who 
underwent coronary angiography were assessed 
for trial eligibility. Of the 2492 patients who met 
the enrollment criteria, 1242 were assigned to the 
iFR group and 1250 to the FFR group (Fig. 1). 
The baseline demographic characteristics of the 
patients are shown in Table 1. The mean age of 
the patients was 65 years, 76% were men, and 
80% had stable coronary artery disease.
Procedural characteristics for the two trial 
groups are shown in Figure 1 and Table 2. A 
total of 99.4% of the patients assigned to the iFR 
group and 99.6% of those assigned to the FFR 
group underwent the assigned procedure. Cross-
over, which represented a deviation from the 
protocol, occurred in 13 cases and was due to 
profound early adenosine-induced bradycardia and 
hypotension in 1 case and to site errors in the 
remaining 12 cases. There were no cases in which 
heart-rhythm disturbances or lack of electrocar-
diographic assessment prevented FFR or iFR 
measurements from being obtained.
The number of vessels evaluated did not dif-
fer significantly between the iFR group and the 
FFR group (total number assessed, 1575 and 
1608, respectively; mean [±SD] number evaluated 
per patient, 1.27±0.61 and 1.29±0.63; P = 0.58). 
The mean iFR and FFR measurements were close 
to their respective thresholds (mean iFR, 0.91±0.09; 
mean FFR, 0.83±0.09); these findings suggest 
that most of the assessed vessels had stenosis of 
intermediate severity (Figs. S4 and S5 in the 
Supplementary Appendix). The number of func-
tionally significant stenoses (i.e., stenoses with 
an iFR or FFR below the treatment threshold) was 
significantly lower in the iFR group than in the 
Figure 1. Enrollment, Randomization, Follow-up, and Analysis.
FFR denotes fractional flow reserve, and iFR instantaneous wave-free ratio.
2492 Underwent randomization
2535 Patients were assessed for eligibility
43 Were excluded
39 Did not meet the inclusion criteria
4 Were unwilling to participate
1242 Were assigned to the iFR group
1234 Underwent iFR-guided assessment
8 Underwent FFR-guided assessment
1250 Were assigned to the FFR group
1245 Underwent FFR-guided assessment
5 Underwent iFR-guided assessment
95 Were withdrawn from the
study before or at 1 yr
7 Had protocol violations
71 Were withdrawn from the
study before or at 1 yr
6 Had protocol violations
1147 Were included in the intention-to-treat analysis
1140 Were included in the per-protocol analysis
1179 Were included in the intention-to-treat analysis
1173 Were included in the per-protocol analysis
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Characteristic
iFR Group 
(N = 1242)
FFR Group 
(N = 1250)
Age — yr 65.5±10.8 65.2±10.6
Sex — no. (%)
Female 280 (22.5) 321 (25.7)
Male 962 (77.5) 929 (74.3)
Disease type — no. (%)†
STEMI 49 (3.9) 42 (3.4)
Acute coronary syndrome 186 (15.0) 184 (14.7)
Stable disease 986 (79.4) 1012 (81.0)
Diabetes — no. (%)
Non–insulin dependent 288 (23.2) 282 (22.6)
Insulin dependent 94 (7.6) 94 (7.5)
Smoking status — no. (%)
Former smoker 461 (37.1) 443 (35.4)
Current smoker 243 (19.6) 262 (21.0)
Hypertension — no. (%) 873 (70.3) 884 (70.7)
Hypercholesterolemia — no. (%) 794 (63.9) 792 (63.4)
Previous myocardial infarction — no. (%) 358 (28.8) 376 (30.1)
Previous percutaneous coronary intervention — no. (%) 489 (39.4) 527 (42.2)
Previous heart condition — no. (%) 489 (39.4) 530 (42.4)
Congestive heart failure — no. (%) 77 (6.2) 67 (5.4)
NYHA class — no. (%)‡
I 21 (1.7) 13 (1.0)
II 28 (2.3) 32 (2.6)
III 16 (1.3) 14 (1.1)
IV 1 (0.1) 3 (0.2)
Impairment of left ventricular function — no. (%)
Mild 147 (11.8) 150 (12.0)
Moderate 65 (5.2) 58 (4.6)
Severe 23 (1.9) 27 (2.2)
CCS angina class — no. (%)§
I 347 (27.9) 305 (24.4)
II 374 (30.1) 370 (29.6)
III 127 (10.2) 154 (12.3)
IV 81 (6.5) 72 (5.8)
Systolic blood pressure — mm Hg 133.9±20.3 134.3±20.1
Diastolic blood pressure — mm Hg 74.9±11.9 75.0±11.8
Heart rate — beats/min 68.9±12.6 69.1±12.8
Body-mass index¶ 27.8±5.0 27.5±5.0
Total cholesterol — mmol/liter 4.1±1.0 4.1±0.9
Hemoglobin — mg/dl 13.9±1.6 13.8±1.6
Creatinine — mmol/liter 90.2±62.0 93.2±81.1
*  Plus–minus values are means ±SD. There were no significant differences between the two groups in baseline character-
istics. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. FFR denotes fractional flow 
 reserve, iFR instantaneous wave-free ratio, and STEMI ST-segment elevation myocardial infarction.
†  In patients with STEMI or an acute coronary syndrome, only nonculprit lesions were evaluated. Patients with STEMI were 
evaluated more than 48 hours after the event occurred.
‡  In the New York Heart Association (NYHA) functional classification system, classes range from I to IV, with higher classes 
indicating greater limitations of physical activity owing to heart disease.
§  In the Canadian Cardiovascular Society (CCS) functional classification system, classes range from I to IV, with higher 
classes indicating greater limitations of physical activity owing to angina.
¶  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Baseline Characteristics of the Patients.*
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FFR group (451 vs. 557 [28.6% vs. 34.6% of total 
vessels evaluated], P = 0.004).
In both the iFR group and the FFR group, the 
number of patients who underwent PCI (565 and 
625, respectively) was greater than the number 
who had functionally significant stenoses (426 
and 486, respectively). This is because PCI pro-
cedures that were performed in culprit vessels of 
patients with an acute coronary syndrome and in 
angiographically significant stenoses (neither of 
which required physiological assessment) were 
included in the totals. The median procedure 
time was significantly shorter in the iFR group 
than in the FFR group (40.5 minutes [interquar-
tile range, 27.0 to 60.0] vs. 45.0 minutes [inter-
quartile range, 30.0 to 66.0], P = 0.001).
Outcomes
At 1 year, the primary end point (a composite of 
major adverse cardiac events) had occurred in 78 
of 1148 patients (6.8%) in the iFR group and in 
83 of 1182 patients (7.0%) in the FFR group 
(Fig. 2). The hazard ratio was 0.95 (95% confi-
dence interval [CI], 0.68 to 1.33; P = 0.78), and 
the difference in risk was −0.2 percentage points 
(95% CI, −2.3 to 1.8; 99% CI, −2.9 to 2.5; 
P = 0.83) (Table 3, and Table S2 in the Supple-
mentary Appendix). The upper limits of the two-
sided 95% and 99% confidence intervals were 
within the prespecified noninferiority margin of 
3.4 percentage points (P<0.001 for noninferior-
ity). The risks of each individual component of 
the primary end point and of death from cardio-
vascular or noncardiovascular causes did not 
differ significantly between the two groups.
The noninferiority of iFR to FFR was also 
confirmed in the per-protocol analysis (Tables 
S4 and S5 in the Supplementary Appendix). In 
the per-protocol analysis, the hazard ratio for 
major adverse cardiac events was 0.94 (95% CI, 
0.67 to 1.31; P = 0.72), and the difference in risk 
was −0.3 percentage points (95% CI, −2.4 to 1.8; 
99% CI, −3.0 to 2.4; P = 0.77). The risk of each 
individual component of the composite end point 
did not differ significantly between the two 
groups in the per-protocol analyses.
Procedural Signs and Symptoms
In the iFR group, 39 patients (3.1%) reported 
adverse procedural symptoms or signs, includ-
ing 19 who reported chest pain and 13 who re-
ported dyspnea (Table 2). In the FFR group, 385 
patients (30.8%) reported adverse procedural 
symptoms or signs, including 250 who reported 
dyspnea and 90 who reported chest pain. The 
difference between the two groups in the num-
ber of patients with adverse procedural symp-
toms or signs was significant (P<0.001) (Fig. S9 
in the Supplementary Appendix). Serious adverse 
events (bronchospasm and ventricular arrhyth-
mias) were reported in 8 patients in the FFR 
group (after hyperemia) and in 1 patient in the 
iFR group.
Discussion
In the DEFINE-FLAIR trial, we found that iFR-
guided coronary revascularization was noninfe-
rior to FFR-guided revascularization with respect 
to the risk of major adverse cardiac events. The 
use of iFR was also associated with a lower rate 
of procedural signs and symptoms and with a 
shorter procedural time than the use of FFR. 
There were no significant differences between 
the trial groups in the rates of death from any 
cause, death from cardiovascular causes, non-
fatal myocardial infarction, and unplanned re-
vascularization. These results suggest that the 
benefits of physiologically guided coronary re-
vascularization with FFR can also be achieved 
with iFR. Our principal findings are similar to 
those now reported in the Journal by Götberg 
et al.16
It has previously been proposed that a hybrid 
iFR–FFR approach might be advantageous for 
the detection of functionally significant steno-
ses, with iFR used as the initial measure and 
FFR used only to evaluate stenoses that were of 
intermediate severity on iFR-guided assess-
ment.17,18 However, the results of our trial sug-
gest that iFR alone can effectively identify steno-
ses that require intervention. Our trial also 
provides clinical evidence that there is no sig-
nificant advantage to the administration of a 
hyperemic agent — a finding consistent with 
results of studies in which iFR and FFR were 
compared with other reference standards.13,14,19,20
Although evidence supporting the benefits of 
physiologically guided revascularization has ac-
cumulated over the past decade, adoption of this 
approach in clinical practice has lagged. There 
are many reasons for this, including equipment 
and drug costs, inadequate reimbursement, phy-
sician preferences, patient symptoms, and addi-
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Variable
iFR Group 
(N = 1242)
FFR Group 
(N = 1250) P Value†
Radial-artery approach — no. of patients (%) 896 (72.1) 888 (71.0) 0.54
Procedure time — min
Median 40.5 45.0 0.001
Interquartile range 27.0–60.0 30.0–66.0
Hyperemic agent administered — no. of patients (% of total no. who 
received a hyperemic agent)
Total NA 1608 (100)
Intracoronary adenosine NA 455 (28.3)
Intravenous adenosine NA 950 (59.1)
Other agent NA 203 (12.6)
Multivessel disease — no. of patients (%) 505 (40.7) 519 (41.5) 0.66
Type of vessel evaluated — no. (% of total vessels evaluated)‡
Total 1575 (100) 1608 (100) 0.58
Left anterior descending artery 844 (53.6) 845 (52.5) 0.56
Left circumflex artery 323 (20.5) 333 (20.7) 0.89
Right coronary artery 374 (23.7) 393 (24.4) 0.65
Other 33 (2.1) 31 (1.9) 0.74
Unknown 1 (0.1) 6 (0.4) 0.06
Total no. of vessels evaluated or treated‡ 1879 1940 0.42
No. of vessels evaluated or treated per patient‡ 1.51±0.76 1.55±0.80 0.42
Functionally significant lesions — no. (% of total vessels evaluated)§ 451 (28.6) 557 (34.6) 0.004
≥1 Functionally significant lesions present — no. of patients (%)§ 426 (34.3) 486 (38.9) 0.02
Mean iFR 0.91±0.09 NA
Mean FFR NA 0.83±0.09
Percent of lesions within the FFR range
<0.60 NA 1.96
0.60–0.90 NA 75.08
>0.90 NA 22.96
Revascularization performed — no. of patients (%)
Total 590 (47.5) 667 (53.4) 0.003
CABG 25 (2.0) 42 (3.4) 0.04
PCI 565 (45.5) 625 (50.0) 0.02
Stents placed — no. (% of total stents placed)
Total 822 (100) 906 (100) 0.86
Drug-eluting stent 811 (98.7) 893 (98.6)
Bioresorbable vascular scaffold 11 (1.3) 13 (1.4)
No. of stents placed per patient 0.66±0.92 0.72±0.96 0.09
Stent length per patient — mm
Median 28.0 28.0 0.74
Interquartile range 18.0–42.0 18.0–44.0
Stent diameter — mm
Median 3.00 3.00 0.44
Interquartile range 2.67–3.25 2.75–3.25
Table 2. Procedural Characteristics.*
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tional procedural burden. Although adenosine is 
a generally safe drug that is used in millions of 
diagnostic procedures annually, its risks are well 
documented21,22 and it is not suitable for every 
patient; therefore, avoiding the use of adenosine 
is preferable.11,23,24 In addition, adenosine contrib-
utes substantially to the cost of physiological 
stenosis assessment, and its use is hampered in 
many countries because it is unavailable or not 
indicated for this purpose. Thus, the ability to 
perform physiological assessments of coronary-
artery stenoses without the use of adenosine 
may increase the use of such assessments in 
clinical practice.
Variable
iFR Group 
(N = 1242)
FFR Group 
(N = 1250) P Value†
Stents placed with postdilation — no. (% of total stents placed) 407 (49.5) 425 (46.9) 0.28
PCI procedures performed with pressure wire — no. (% of total  
stents placed)
261 (31.8) 278 (30.7) 0.63
Patient-reported adverse procedural symptoms or signs  
— no. of patients (%)
39 (3.1) 385 (30.8) <0.001
Patient-reported dyspnea — no. of patients (%) 13 (1.0) 250 (20.0)
Patient-reported chest pain — no. of patients (%) 19 (1.5) 90 (7.2)
Physician-reported adverse procedural signs — no. of patients (%)
Heart-rhythm disturbance 2 (0.2) 60 (4.8)
Significant hypotension 4 (0.3) 13 (1.0)
Vomiting or nausea 1 (0.1) 11 (0.9)
Ventricular arrhythmia or bronchospasm¶ 1 (0.1) 8 (0.6)
Other 4 (0.3) 38 (3.0)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. CABG denotes coronary-artery 
bypass grafting, NA not applicable, and PCI percutaneous coronary intervention.
†  P values that compare distributions were calculated by means of the Wilcoxon rank-sum test. P values that compare 
percentages were calculated by means of a test for proportions.
‡  Evaluated vessels are vessels that underwent physiological assessment. Treated vessels are vessels that underwent PCI.
§  Functionally significant lesions are lesions with an iFR or FFR equal to or lower than the treatment threshold (0.89 and 
0.80, respectively).
¶  Serious adverse events included ventricular arrhythmias and bronchospasm; one case of ventricular arrhythmia occurred 
in the iFR group, and one case of ventricular arrhythmia and seven cases of bronchospasm occurred in the FFR group.
Table 2. (Continued.)
Outcome iFR Group FFR Group Difference in Risk P Value
no./total no. (%)
percentage points 
(95% CI)
percentage points 
(99% CI)
Primary end point: death from any cause,  
nonfatal myocardial infarction, or  
unplanned revascularization
78/1148 (6.8) 83/1182 (7.0) −0.2 (−2.3 to 1.8)† −0.2 (−2.9 to 2.5) 0.83
Unplanned revascularization 46/1147 (4.0) 63/1181 (5.3) −1.3 (−3.0 to 0.4) −1.3 (−3.1 to 1.9) 0.13
Nonfatal myocardial infarction 31/1148 (2.7) 28/1180 (2.4) 0.3 (−1.0 to 1.6) 0.3 (−1.4 to 2.0) 0.62
Death from cardiovascular causes 7/1147 (0.6) 4/1179 (0.3) 0.3 (−0.3 to 0.8) 0.3 (−0.5 to 1.0) 0.34
Death from noncardiovascular causes 15/1147 (1.3) 9/1179 (0.8) 0.5 (−0.3 to 1.4) 0.5 (−0.5 to 1.6) 0.19
Death from any cause 22/1147 (1.9) 13/1179 (1.1) 0.8 (−0.2 to 1.8) 0.8 (−0.5 to 2.1) 0.11
*  Patients who had a myocardial infarction or an unplanned revascularization before withdrawing from the study were included in the analyses.
†  For the primary end point, the upper limit of the 95% confidence interval was 1.8 percentage points, which was within the prespecified non-
inferiority margin of 3.4 percentage points.
Table 3. Outcomes for Difference in Risk at 1 Year.*
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Although the patients were not informed of 
their group assignments, adverse procedural 
symptoms or signs occurred in 30.8% of the 
patients in the FFR group, as compared with 
3.1% of the patients in the iFR group. This dif-
ference is most likely due to the side effects of 
adenosine. It is therefore possible that at least 
some patients in the FFR group became aware of 
their group assignment. Such unblinding could 
have led to bias in the rates of unplanned revas-
cularization, especially if patients discussed these 
symptoms with their physicians.
The number of functionally significant steno-
ses was lower in the iFR group than in the FFR 
group. This difference could be a consequence 
of dissimilar thresholds for the two measures. 
In addition, iFR has been shown to be more 
closely linked to coronary f low reserve than 
FFR, and a previous study has shown higher 
revascularization rates associated with assess-
ment guided by FFR than with assessment 
guided by coronary flow reserve.25 Regardless of 
the explanation, the results of our trial suggest 
that the use of iFR can lead to outcomes similar 
to those associated with FFR and to the place-
ment of fewer (potentially unnecessary) stents.
The clinical population in our trial differed 
from the population in the FAME trial (Fractional 
Flow Reserve Versus Angiography for Multivessel 
Evaluation), in which all the patients had multi-
vessel disease and were scheduled for revascular-
ization.6 In DEFINE-FLAIR, only 41% had multi-
vessel disease. Although the benefit of coronary 
revascularization in patients with single-vessel 
disease is likely to be more uncertain, our trial 
population is probably similar to the population 
that would be seen in current clinical practice. 
Given the clinical evidence in support of physi-
ologically guided revascularization, it was con-
sidered unethical to repeat a study similar to 
FAME, in which iFR-guided revascularization was 
compared with angiography-guided revascular-
ization.
In our trial, the noninferiority margin for the 
difference in risk was set at 3.4 percentage 
points, which meant that the upper limit of the 
hazard ratio could have been as high as 1.40 
while still allowing a claim of noninferiority. 
Although this noninferiority margin is wide, it is 
similar to margins used in other major clinical 
trials in cardiology.26-32 The event rates were 
lower than had been expected, because the num-
ber of patients with an acute coronary syndrome 
who were enrolled in the trial was lower than had 
been anticipated. However, when we used the pre-
specified noninferiority margin to test the ac-
tual event rate among the prespecified number 
of patients, we found that iFR was noninferior to 
FFR even when the upper limit of a one-sided 
99.5% confidence interval was used.
In conclusion, we found that coronary revascu-
larization guided by iFR was noninferior to re-
vascularization guided by FFR with respect to 
major adverse cardiac events at 1 year. The rate 
of adverse procedural signs or symptoms was 
lower and the procedure time was shorter in the 
iFR group than in the FFR group.
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Figure 2. Cumulative Risk of the Primary End Point.
Shown is the cumulative risk of the composite of death from any cause, 
nonfatal myocardial infarction, or unplanned revascularization at 1 year. 
The inset shows the same data on an enlarged y axis.
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